Mathes Company Inc. Has $904,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Mathes Company Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 13.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,300 shares of the biopharmaceutical company’s stock after selling 5,200 shares during the period. Mathes Company Inc.’s holdings in Pfizer were worth $904,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the second quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the second quarter valued at approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.3 %

NYSE:PFE opened at $29.75 on Thursday. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11. The stock’s fifty day moving average price is $29.33 and its two-hundred day moving average price is $28.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market cap of $168.58 billion, a P/E ratio of -495.75, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the company earned $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.65%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.